|
3.6 PRÉVENTION - ACTIVITÉ PHYSIQUE
|
|
|
|
4.2 DÉP., DIAG. & PRONO. - GÉNOME
|
|
|
|
5.12.10 IMMUNOTHÉRAPIES - FUSIONS ET ACQUISITIONS
|
|
|
|
5.12.6 IMMUNOTHÉRAPIES - AMM
|
|
|
|
|
|
5.2 PHARMA
|
|
|
|
5.2.3 PHARMA - ÉCONOMIE
|
|
|
|
5.2.6 PHARMA - BIOTECH
|
|
|
|
After a PhIII failure, the FDA delivers Blueprint an expected CRL [EndPoints]
|
|
|
|
|
|
The best promise for GIST patients without the PDFRa mutation now lies with Deciphera, which has been going to head to head with Blueprint on the indication for a year. The company’s drug, ripretinib, has earned a breakthrough designation and a priority review for fourth-line GIST, setting up a decision in August.
|
|
|
|
|
|
|
5.3.4.1 TRAITEMENTS - AMM (FDA, EMA,...) - RUCAPARIB
|
|
|
|
|
5.3.4.2 TRAITEMENTS - AMM (FDA, EMA,...) - RIPRETINIB
|
|
|
|
|
|
5.5.1.1 ASCO (GÉNÉRAL) - INDUSTRIELS
|
|
|
|
5.5.15 ASCO (BIOPSIES LIQUIDES)
|
|
|
|
5.9.3 EHA
|
|
|
|
6.1 OBSERVATION
|
|
|
|
6.15 LUTTE CONTRE LES CANCERS - COVID-19
|
|
|
Protecting “covid-protected” cancer hubs [BMJ]
|
|
|
|
|
|
For truly “covid-protected” cancer treatment, it will therefore be essential to regularly screen asymptomatic staff in cancer hubs who interact with patients, and who may be carriers of covid-19.
|
|
|
|
|
|
|